Mike Anderson a 40+ year veteran of the pharmaceutical industry has broad leadership experience in branded products, generics, and medical instruments. He currently is employed as the CEO of New American Therapeutics and founded a specialty pharma company, Eclat Pharmaceuticals, in 2010, eventually selling the company to Flamel Technologies, a French drug delivery company. He served as the CEO of Flamel (later named Avadel Pharmaceuticals) from 2012 until 2019. During his tenure at Avadel, the company progressed from never having been profitable, without any revenue, to a profitable specialty pharma company with 3 approved NDAs. Prior to that Anderson was the CEO of Ther-Rx Corporation, a women’s healthcare business and the CEO of ETHEX Corporation, a generic drug company. He started his career at A. H. Robins Company and also worked in management at Schein Pharmaceutical. Anderson has a Bachelor of Arts degree from the University of Georgia.
Phil Thompson has 18 years’ experience in the pharmaceutical business. He was formerly with Avadel Pharmaceuticals where he served as a Senior Vice President, General Counsel, and Corporate Secretary. Mr. Thompson was instrumental in the company’s relocation from France to Ireland and effectively handled all aspects of the company’s SEC reporting, commercial, and transactional activities. He is
experienced and expert in compliance, Intellectual Property, and Human Resources. He was a key member of Avadel’s commercial strategic leadership. Prior to his work at Avadel, Mr. Thompson served as the Vice President of Legal Affairs at West-Ward Pharmaceutical, General Counsel at Paddock Laboratories, and VP, Strategic Business Transactions at KV Pharmaceutical. He started his
pharmaceutical career at Barr Pharmaceuticals as the Associate General Counsel. Mr. Thompson also worked at White & Case, LLP in New York. He is a graduate of Washington University, has both MBA and Juris Doctor degrees from the University of Michigan.